Percutaneous biopsy of pediatric solid tumors

Diagnostic accuracy of less invasive procedures in pediatric oncology remains understudied. Prior research has shown that open biopsies carry higher risks and longer recovery times. However, the reliability of percutaneous alternatives for solid tumors in children is unclear. No prior work had resolved whether image-guided needle biopsies could reliably replace surgical approaches in this population. This gap motivated a retrospective evaluation of diagnostic performance in a pediatric setting. The study aimed to address whether percutaneous biopsy could match open biopsy in diagnostic yield. The focus was on solid tumors, where tissue sampling is essential for staging and treatment planning. The authors sought to assess diagnostic accuracy in both initial diagnosis and recurrence scenarios. Their findings could influence clinical guidelines for diagnostic approaches in pediatric oncology.

The study aimed to evaluate the diagnostic accuracy of percutaneous biopsy in pediatric solid tumors. The specific problem addressed is whether a less invasive method could reliably replace open biopsy. The motivation stems from the need to reduce surgical risks in young patients. The authors sought to determine sensitivity, specificity, and overall accuracy of the procedure. They focused on both initial diagnosis and suspected recurrence cases. The study design involved retrospective analysis of clinical data over a defined period. The goal was to assess whether percutaneous biopsy could serve as a primary diagnostic tool. The outcomes would inform clinical decisions regarding biopsy techniques in pediatric oncology.

The researchers conducted a retrospective analysis of clinical records. They reviewed data from 202 percutaneous core-needle biopsies performed at a children's hospital. The procedures occurred between 1997 and 2003, covering a five-and-a-half-year span. Biopsies were guided using ultrasound, CT, or fluoroscopic imaging. Each tumor yielded 1 to 17 core samples, with a median of six samples per case. Needle sizes ranged from 13 to 20 gauge, with a median of 15 gauge. Tissue samples underwent histopathologic and ancillary testing. Diagnostic accuracy was confirmed through surgery or follow-up outcomes.

The study found 121 true-positive results out of 135 cases, yielding 90% sensitivity. There were 67 true-negative results, resulting in 100% specificity. Fourteen cases had false-negative results, leading to 93% overall accuracy. In initial diagnosis cases, sensitivity reached 97% with 100% specificity. Accuracy in these cases was 98%, indicating strong performance. For suspected recurrence, sensitivity dropped to 83% while specificity remained at 100%. Overall accuracy in recurrence cases was 88%, slightly lower than initial diagnosis. The procedure demonstrated high diagnostic accuracy across both diagnostic contexts. These findings suggest percutaneous biopsy is reliable for pediatric solid tumors.

The authors concluded that percutaneous biopsy is highly accurate for pediatric solid tumors. Their findings suggest this method may replace open biopsy in many cases. The procedure demonstrated 93% overall accuracy in malignancy detection. For initial diagnosis, the accuracy reached 98%, indicating strong reliability. In recurrence cases, accuracy was 88%, still above acceptable diagnostic thresholds. The authors propose that percutaneous biopsy is a safe alternative to surgical approaches. They emphasize the diagnostic value of image-guided techniques in pediatric oncology. These results support the use of percutaneous biopsy as a primary diagnostic tool.